NICE recommends Novartis’ Mayzent on the heels of SMC approval
Drug is licensed for secondary progressive multiple sclerosis with active disease
Read More
Tag: Mayzent
NICE rejects Novartis’ Mayzent for secondary progressive MS
NICE says the cost-effectiveness of the drug is uncertain, but Novartis says the decision denies patients access to the first licensed oral therapy for SPMS with active disease
Read More
Novartis highlights benefits of Mayzent in MS
The data underscore the advantages of early treatment initiation, the firm notes
Read More
Novartis’ MS drug gets FDA approval
The FDA has approved Novartis’ multiple sclerosis drug, Mayzent.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
